Introduction
HMG CoA reductase inhibitors (statins) lower low-density lipoprotein cholesterol (LDL-c) and are effective in reducing adverse cardiovascular (CV) events in both primary and secondary preventions. 1, 2 The magnitude of benefit relates closely to the attained level of plasma LDL-c; and large-scale meta-analyses have suggested that for each 1 .0 mmol/L reduction of LDL-c the annual rate of major CV events could be reduced by about 20%. 3 In spite of this, a substantial proportion of individuals on intensive lipid therapy continue to experience adverse CV 'events'. 4 The pathologies underlying those events are likely to be heterogeneous and an important question remains as to whether such risk could be reduced further and whether a strategy based on patient characterization and rational selection of intensified therapies might be beneficial. For this purpose a number of lipid and blood biomarkers have been proposed (i) as 'stratification' tools and (ii) as potential therapeutic targets. These range from non-LDL lipid parameters such as triglycerides, 5 high-density lipoprotein cholesterol (HDL-c), 6 and cholesterol efflux capacity; 7 to the functionally pleotropic properties of lipoprotein particles; 8 even to serum and cellular biomarkers of inflammation, such as serum C-reactive protein, 9 serum amyloid A, 10 circulating monocyte subsets, 11 and lipoprotein-associated phospholipase A2 (Lp-PLA2), 12 which are intricately linked with the initiation, progression, and experimental regression of atherosclerosis. 13 Nonetheless, the interactions amongst different lipid and blood biomarkers are complex and little has been adopted into routine clinical practice. 4, 14 With recent advances in vessel wall imaging, plaque characterization can now provide serial measurement at the target lesion level, which might enable us to directly probe the relationship between plasma lipids and atherosclerosis. 15 In this article, we will discuss various recent strategies deployed in lipid intervention to combat atherosclerosis and how novel plaque imaging techniques might help to refine and rationalize the use of emerging lipid-lowering agents on the clinical horizon.
LDL cholesterol lowering therapy-'lower is better'
LDL-c has been recognized as major predictor of future major CV events. 16 Statin intervention to lower LDL-c has been consistently successful. 3 In the Scandinavian Simvastatin Survival Study (4S), lowering cholesterol with simvastatin improved survival in patients with coronary heart disease; with an absolute risk reduction of 3.7% over 6 year follow-up. 1 Moreover, intensive statin therapy using high dose atorvastatin continued to show benefits in reducing deaths, myocardial infarction (MI), strokes, and revascularizations when compared with standard statin regimen of pravastatin. 2 These benefits were attributed to the lower achieved LDL-c of 62 mg/dL in the atorvastatin group compared with the 95 mg/dL in the pravastatin group. Furthermore, Baigent et al. 3 have shown that improvement in CV outcomes is proportional to the degree of LDL-c reduction and for every 1 mmol/L (38.7 mg/dL) reduction in LDL-c levels there is a 23% relative reduction in the risk of major coronary events over 5 years.
The consistent, and seemingly predictable, association between attained LDL-c and CV risk in statin trials has added support to the notion of LDL-c as causative in atherosclerosis and its complications, and fuelled the proposition that 'lower is better' in relation to LDL-c.
Ezetimibe
Studies of other classes of non-statin drugs appeared to also support this LDL theory. For instance, ezetimibe, which blocks NPC1L1 protein and reduces intestinal absorption of cholesterol, 17 provided a unique and 'clean' mechanism in targeting LDL-c hence an excellent opportunity to test further the effects of LDL-c reduction in isolation. Indeed, the IMPROVE-IT (The Improved Reduction of Outcomes: Vytorin Efficacy International Trial) trial has shown that treatment with ezetimibe, in addition to statin therapy, further reduced LDL-c and this was translated into further clinical benefits in patients after acute coronary syndromes. 18 Adding ezetimibe to simvastatin led to an additional 2% absolute risk reduction of cardiac death, MI, and strokes at median follow-up of 6 years. This was the first study to show the additional incremental benefits of non-statin lipid-modifying drugs on CV outcomes and this benefit was proportional to the difference in LDL-c between two groups. 18 That said, these are patients who were not selected on the basis of any identified or projected propensity to gain from further LDL-c reduction and the magnitude of the benefit was small (and accrued over a prolonged period), despite the very low levels of attained LDL-c (53.7 mg/dL)
Proprotein convertase subtilisin-kexin type 9 inhibitors
Evolocumab and alirocumab are fully human, while bococizumab is humanized monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9). [19] [20] [21] Circulating PCSK9 binds to LDL receptors on the cell surface leading to degradation rather than recycling of LDL receptors, resulting in increasing LDL-c concentrations. 22 As such, preserving LDL receptors by inhibiting PCSK9, e.g. using evolocumab or alirocumab, leads to marked LDL-c reduction. 19, 20, 23 In fact, both drugs are very effective in reducing plasma LDL-c level (by approximately 60% when added to statins). 19, 20 This LDL-c reduction was superior to ezetimibe when compared headto-head in patients not taking statins (due to apparent statin intolerance). 24 In the GAUSS-3 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects 3) randomized clinical trial, evolocumab caused an absolute reduction of 103 mg/dL of LDLc in 24 weeks compared with 31 mg/dL using ezetimibe (P < 0.01). 24 Both, alirocumab and evolocumab, have been approved by Food and Drug Administration for additional LDL-c reduction in patients with familial hypercholestermia or atherosclerotic CV disease in 2015. 25, 26 However, whether the marked LDL-c reduction will be translated into difference in clinical outcomes is still uncertain. In an exploratory analysis, it was suggested that there might be potential benefit in reducing future CV events. 19, 20 However, this reduction was only marginal and the absolute risk reduction was small, on average 1 21 The magnitude of benefit in preliminary published data suggests that using PCSK9 on 'all comers' might not be practical (or desirable). Moreover, recent cost-effective analysis performed by Kazi et al. 30 showed that adding PCSK9 to statins in patients with atherosclerotic CV disease would be estimated to increase health care costs substantially at $414 000 per QALY. This would be a significant limitation for these drugs and therefore highlight the urgent need for risk stratification.
Targeting non-LDL-c-some high-profile trial failures
In order to combat residual risk following statin treatment, considerable efforts had been focused on non-LDL-c parameters.
Epidemiological data have consistently suggested that low plasma HDL-c is an independent risk factor for future CV events. 8, 16 However, Mendelian randomization studies did not support the causal role of HDL-c, thereby, challenging the concept that raising HDL-c will reduce CV risks. 31 Using multiple single nucleotide polymorphisms previously identified with established associations with plasma HDL-c, triglycerides, and LDL-c as instrumental variables for Mendelian randomization, a recent large-scale meta-analysis including 62 199 patients with 12 099 coronary heart disease events, has demonstrated that whilst alleles associated with LDL-c and triglycerides are linked with CHD event rates-hence supporting a causal effect-alleles associated with HDL-c, after adjustment for triglycerides, LDL-c, and statin use, had no effect on coronary heart disease (CHD) event rates. 31 Moreover, a recent study demonstrated that a variant in scavenger receptor B1 profoundly raises HDL-c but with increased risk of CV events (OR 1.79, P = 0.018). 32 This lends further credence to the notion that flux of cholesterol mediated by HDL may be more important than the level of HDL-c and may provide an explanation, among other causes, for failure of HDL-c raising therapies. It also emphasizes the importance of developing clinically accessible diagnostic tools that quantify relevant biological processes, based on a clear understanding of the underlying biology.
Cholesteryl ester transfer protein inhibitors
Cholesteryl ester transfer protein (CETP) inhibition is an example of an HDL-c raising therapy. 33, 34 CETP promotes bidirectional transfer of cholesteryl esters and triglycerides between plasma lipoprotein particles, predominantly VLDL and HDL. 35 Inhibition of CETP, therefore, alters the bidirectional equilibrium and increases plasma concentration HDL-c, while decreasing proatherogenic LDL-c. 33, 34 Torcetrapib was the first member of the CETP inhibitors to be tested in a Phase III clinical trial. 36 It increased HDL cholesterol by 70% and decreased LDL-c by 25%. 36 Despite this potentially beneficial lipid profile, the ILLUMINATE (the Investigation of Lipid Level Management to Understand Its Impact in Atherosclerotic Events) trial was prematurely terminated due to an excess of adverse events, including mortality, in the torcetrapib group. 36 The precise cause for the adverse outcomes is not known, but torcetrapib had an 'off-target' effect of raising blood pressure by 5 mm Hg. Other factors such as increase in aldosterone and impaired endothelial function may also be relevant. 37 These effects were independent of CETP inhibition and it was initially thought to represent failure of torcetrapib as molecule rather than through its CETP inhibitory properties. 38 However, other CETP inhibitors which do not share molecular similarity as torcetrapib were also unsuccessful in reducing CV risk. 39 Dalcetrapib did not have the off-target toxicity reported with torcetrapib, but results from the dal-OUTCOMES did not show risk reduction of CV events. 39 It was argued that dalcetrapib had only modest effect on raising HDL with minimal effect on LDL and that potentially explained its failure. 35 Interestingly, both torcetrapib and dalcetrapib did not show any pronounced effect on atherosclerosis progression or regression using various imaging modalities. 40, 41 In the
ILLUSTRATE (Investigation of Lipid Level Management Using
Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) trial, torcetrapib did not change the progression of percentage atheroma volume assessed on intravascular ultrasonography when compared with atorvastatin. 40 In addition, in the dal-PLAQUE trial all magnetic resonance imaging (MRI) structural changes of arterial wall were similar between dalcetrapib and placebo, after 24 months of therapy. 41 More recently, another candidate CETP inhibitor, evacetrapib, was evaluated in the ACCELERATE study in patients with high-risk vascular disease. 42 However, this study was yet again terminated due to lack of efficacy. Despite 130% increase in HDL-c and 37% reduction in LDL-c, the primary composite endpoint of death, MI, stroke, coronary revascularization, and unstable angina was comparable between evacetrapib and placebo (12.8% vs. 12 .7%, respectively, P = 0.85). 43 At the time of writing, only one remaining member of CETP inhibitors, anacetrapib, is currently being evaluated. Early phase studies confirming safety with no apparent off-target toxicity; 33 however, whether this will translate to clinical outcome benefits is being studied in the REVEAL (Randomized EValuation of the Effects of Anacetrapib Through Lipidmodification) trial, 44 which is expected to report in 2017.
Peroxisome proliferator-activated receptor-a and -c dual agonists
Fibric acid derivatives (fibrates) are peroxisome proliferatoractivated receptor (PPAR)-a agonists, activation of which upregulates transcription of the major HDL apolipoproteins, Apo-AI and Apo-AII. 45 As such, fibrates demonstrate the expected biological effect in effectively reducing triglycerides level, and raising plasma HDL-c. 46 At the same time, thiazolidinediones, being an example of PPAR-k agonists, have been used to restore insulin sensitivity in the treatment of T2DM since the late 1990s. 47 This class of agents appears to be beneficial in surrogate marker studies of CV disease. 48 PPAR-c is essential in adipogenesis and is a key regulator to control lipid metabolism. 49 As such, there has been an interest in exploring the clinical effects of combined dual PPAR-a/c agonism. However, a whole class of cardiometabolic agents, the glitazars, which are PPAR-a/c dual agonists despite showing very encouraging (results in) preclinical and Phase II studies, 50 had suffered ill-fate with development terminated in latephase trials due to specific safety concerns 51 or lack of efficacy. 52 
Nicotinic acid/niacin
For over 50 years, nicotinic acid (NA) has been known to exert 'favourable' effects on plasma lipoproteins. 53 It reduces atherogenic lipoproteins LDL-c, VLDL-c, and Lp(a), and is the most efficacious drug (except for CETP inhibitors) to raise plasma HDL-c (by up to 30%). 54 The Coronary Drug Project 55 had shown benefits of NA in reducing CV events and mortality in patients with coronary heart disease, a finding supported by two recent meta-analyses. 56, 57 In addition to its lipoprotein-mediated effects, activation of its cell surface G-protein-coupled receptor GPR109A with NA also antagonizes known inflammatory pathways in adipocytes 58 and in some leucocytes. 59 Despite the success of NA in early trials, in larger CV outcome study such as the AIM HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial, 60 NA did not further reduce CV events in low-risk studied population (stable CV disease with exclusion of acute events). Ezetimibe usage was a potential criticism in the failure of this trial as its use was not controlled in niacin and placebo groups, which may have influenced the results as one would anticipate from the subsequent results of the ezetimibe study IMRPOVE-IT. 18 Only 1 in 10 of NA group received ezetimibe compared with one in five in the statin group, which might potentially offset any anticipated benefit from NA. Nonetheless, in a subsequent large-scale outcome trial HPS2-THRIVE (The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events), NA was again shown not to confer any additional benefit in reduction in major vascular events in optimally statintreated patient. 61 In fact, there was a non-significant 9% proportional increase in NA group from all-cause (both vascular and non-vascular) mortality. 61 Common themes for recent drug development failures
As seen from various examples above, there had been considerable efforts in anti-atherosclerotic drug development over the last decade. However, for a majority of these compounds, despite promising early phase/surrogate biomarker clinical studies, they mostly fell at the final hurdle in translating into clinical outcome benefits. One potential reason is that in the post-statin era, any new pharmacological agent not only has to show clinical benefits on its own, as monotherapy, but also has to demonstrate incremental benefits in addition to statin as an adjunctive therapy, since it is no longer ethically acceptable to conduct clinical trials randomizing statin therapy in high-risk patients. Furthermore, recent American Heart Association/European Society of Cardiology cholesterol treatment guidelines have resulted in progressive lowering of LDL-c treatment threshold. 62, 63 As a result of this, and other effective interventions, newer agents are confronted with increasing challenges in demonstrating efficacy in clinical outcome trials. A further and recurring issue has been the lack of thorough mechanistic understanding of the modes of action of lipidmodification drugs. For instance, niacin was used for many years to lower LDL-c (and raise HDL-c) with no clear understanding of its mechanism of lipoprotein modification or even knowledge that it exerted anti-inflammatory effects through activation of G-proteincoupled receptor GPR109A. 64 Similarly, the direct effects of CETP inhibition on the exchange of neutral lipids are quite well understood, with detailed structural knowledge of CETP and its ability to physically bridge lipoproteins. 65 However, although the effects of CETP inhibition on HDL-c (and sometimes LDL-c) are striking, there is little or no appreciation of the functional implications of CETP inhibition in respect of cholesterol fluxes. Much needed 'targeting' and 'stratification' tools should incorporate a mechanistic element. Another very significant challenge is that the trial population might simply be too heterogeneous to demonstrate small incremental benefits using therapies that are not targeted to a specific mechanism or identifiable patient characteristic. In other words, the processes responsible for recorded 'events' might include lipoprotein-driven atherogenesis, thrombosis, 'inflammation', dysrhythmia, etc. Refinement of the target treatment group might allow signals of benefit to be detected above noise, whilst minimizing potential harmful sideeffects. What is needed is a means of 'mechanistic staging' to identify subgroup of patients that might benefit from targeted therapy. This apparent disconnect between early-phase biomarker studies and clinical outcome trials in the current drug evaluation platform might also reveal how incomplete understanding of surrogate biomarkers (including imaging features) limits their usefulness in drug development. For example, Libby et al. have recently challenged the notion that 18 FDG-PET imaging of atherosclerotic plaque is a faithful reported of 'inflammation' as hypoxia rather than inflammation drives the cellular accumulation of glucose that generates the 18 fludeoxyglucose positron emission tomography (FDG-PET) signal. 66 Another consequence of failure to stratify patients is that the absolute risk reduction is getting smaller for any new drugs given the concurrent advances in both mechanical and pharmacotherapy interventions. This is reflected by the large NNT in the cases of both ezetimibe and PCSK9 inhibition. Overall, the unselective nature of using lipid lowering drugs, in addition to statins, has been proved to be fruitless so far. This exposes the urgent need to establish risk stratification tools that identify high-risk subgroups and effectively exclude low-risk one where the latter may 'dilute' any potential benefit from the new drug. Identifying high-risk groups, using imaging or other biomarkers, should also match the mechanism of the used drug. In the case of LDL-reduction drugs, a putative mechanism for the clinical benefits of LDL-c lowering therapies is through promoting net depletion of lipid from lipid-rich necrotic core (LRNC) in atherosclerotic plaques, with replacement by fibrous tissue and consequent 'plaque stabilization '. This matching is what we refer to as mechanistic staging. Some imaging approaches could identify higher risk patients; however, their ability to report on target processes or even response to treatment may be limited. For instance, calcification detected on CT could be used to identify both high-and low-risk individuals for future cardiac events as a surrogate of elevated coronary plaque burden. 67, 68 Therefore, it is inviting to use this technique as screening tool to establish patients for 'go' vs. 'no-go' in patients selection for new drugs. However, it is still uncertain what part of the atherosclerosis process is reflected by coronary calcification and subsequently its role as a biomarker is yet to be determined. 69 Moreover, statins can increase coronary calcifications despite the reduction in plaque volume 70 and, therefore, calcification would not be a good target to track effect of lipid lowering drugs. In fact, this imaging biomarker is an example of non-mechanistic staging where although it recognizes the high risk category, it does not provide mechanistic insights on how a given drug is targeting the disease characteristic. Similarly molecular imaging using 18 F-NaF has also been shown to distinguish between culprit and non-culprit plaques. 71 It was also demonstrated that elevated tracer uptake was associated with patients with highrisk plaque feature such as large necrotic core, micro-calcification, and positive remodelling. 71 Whether lipid lowering drugs will result in reducing tracer uptake or promote their transition into macrocalcification as part of healing process is still to be tested. Overall, not every imaging modality could be utilized to identify and track response to lipid lowering drugs, but the application of any imaging modality should rather be tailored to these drugs' mechanism of action that enables us to estimate atherosclerotic burden or more importantly atherosclerotic lipid content (see Table 1 ).
Current role of imaging in plaque characterization
In experimental coronary atherosclerosis, greater luminal crosssectional area was achieved using cholesterol-free diets supporting the hypothesis of atherosclerosis regression. 72 Others have demonstrated in rabbits that low cholesterol diet did not only decrease cholesterol content within aortic plaques, but also increased the deposition of collagen. 73 Thereby, reduction in plasma LDL-c has been associated with depletion of plaque lipid content and changes in plaque composition. In a small human study, analysis of explanted carotid endarterectomy specimens in patients treated with statins has shown lipid core depletion compared with placebo. 74 It supports the hypothesis that using lipid-lowering therapy to reduce plasma LDL-c may lead to net depletion of cholesterol from atherosclerotic plaque; and that, in turn, might have a 'stabilizing effect' on plaques. This process of cholesterol clearance is a manifestation of 'reverse cholesterol transport' in which HDL is thought to play an important role. 75 This lipiddepletion theory, driven by change in plasma lipoproteins, has been investigated on both invasive and non-invasive imaging techniques.
Invasive coronary imaging-from lumen to vessel wall
Early evidence from the Multicentre Anti-Atheroma Study (MAAS) showed that 20 mg simvastatin daily over 4 years slowed progression of diffuse and focal coronary atherosclerosis. 76 This statin effect was small in absolute terms, as there was only 0.06 mm increase in the lumen diameter compared with 0.08 mm reduction with placebo using quantitative angiography. As atherosclerotic processes begin within the vessel wall long before encroachment on the lumen is detectable by techniques of contrast lumenography, this observation might be expected due to the relative insensitivity of angiography to detect small changes in plaque volume. 77 In support of this, the clinical benefits established by statin trials in the same era, such as 4S, 1 were not matched by the plaque regression quantified on invasive lumenography. Simvastatin use in the 4S showed >40% relative risk reduction in coronary deaths compared with placebo. 1, 76 The effect of lipid-lowering therapy on cardiac events is therefore much greater than the effect appreciated on angiographically determined progression or regression of atherosclerosis. In view of the insensitivity of lumenography to assess atherosclerotic processes within the vessel wall, other invasive imaging modalities, such as intravascular ultrasound (IVUS) and near infra-red spectroscopy (NIRS), have been developed to assess plaque regression (Figure 1) . Using the former technique, Nissen et al. 79 showed that in patients with angiographically documented coronary artery disease, intensive statin therapy (atorvastatin 80 mg) was associated with slower progression of atherosclerosis compared with moderate dose of statin (pravastatin 40 mg). This was significantly related to the level of LDL-c where the greater reduction of LDL-c was associated with the slower rate of progression on IVUS. However, these modest changes in plaque burden still do not fully explain the CV risk reduction seen with LDL-c reduction.
2,80
A number of studies have used IVUS-coupled virtual histology (IVUS-VH) to track changes in plaque composition over time with lipid lowering treatment. 81, 82 Park et al. 82 demonstrated in a recent randomized trial that rosuvastatin reduced per cent necrotic core volume from 21.3% to 18% over 12 month follow-up, whereas fibro fatty volume increased from 11.7% to 14.8% suggesting statin-induced change in plaque composition. To further enhance the sensitivity in detecting subtle plaque compositional changes, NIRS was recently developed. NIRS provides direct analysis of plaque chemical composition and has been particularly useful in the identification of lipid-rich plaques. 83 This technique was recently used to show, in the YELLOW (Reduction in Yellow Plaque by Aggressive Lipid-Lowering Therapy) trial, 84 that short-term intensive rosuvastatin reduces lipid content in haemodynamically significant human coronary lesions. Lipid core burden reduction was greater in the intensive statin group (rosuvastatin 40 mg) over 7 week follow-up. Other markers of plaque stability such as thickness of fibrous cap were not studied in this trial; however, authors have set up the YELLOW II trial where optical coherence tomography (OCT) will be performed to address the relationship between change in plaque composition on NIRS and OCT and high dose statin therapy. 85 Despite its promising potential, the invasive nature of catheter-based imaging techniques critically limits its wider adoption in patients with subclinical atherosclerosis, especially in a clinical trial setting. 89 This multicontrast technique has been shown to accurately delineate different plaque components, namely fibrous cap, LRNC, intraplaque haemorrhage (IPH), and calcification with high sensitivity and specificity. 90 The lipid-depletion hypothesis was tested in a prospective MRI study on carotid plaque composition over a time-course of 3 years. 91 In this study, patients with measurable LRNC were started on a combination of high-intensity lipid-lowering therapies and annual serial MRI was performed for 3 years. The time-course showed that %LRNC decreased by about 3% per year in the first 2 years and decreased from a total of 14.2% to 7.4% after 3 years of treatment. Similar results had also been demonstrated using rosuvastatin. 92 Nonetheless, in vivo evidence in humans that demonstrate plaque compositional change on CV outcomes remains sparse. Indeed, changes in plaque components and their influence on future events are inferred from histological studies that had characterized high-risk plaque features following acute athero-thrombotic events. Pathological features and observations of ruptured and non-ruptured plaques post-mortem were extrapolated to infer insights into the high-risk features of vulnerable plaque. 93 Fibrous cap thickness was the best discriminator of plaque type followed by macrophage infiltration and necrotic core size. 94 These features may distinguish ruptured plaques and identify high-risk or vulnerable ones. In addition, in the carotid arteries, IPH is an independent predictor of future CV events. 95 Redgrave et al. 96 demonstrated that symptomatic carotid plaques have a high prevalence of cap rupture, large lipid core, intra-plaque haemorrhage, and dense macrophage infiltrate. Similar findings were reported in coronary artery disease. 97 Plaque composition is likely to play an essential role in progression of acute coronary events. 85, 98 It is important to emphasize that targeting lipid-relevant processes of atherogenesis (mechanistic staging) is a different approach than pursuing vulnerable plaque (risk assessment). For instance, thin cap fibro atheroma (TCFA) is an assembly of different features within atherosclerotic plaque and does not reflect a single disease process pathway. In fact, pursuing vulnerable plaque has failed to have any major impact on clinical events. 69 It appears therefore logical to focus on changes in plaque composition with lipid lowering treatment in addition to plaque volume, potentially in second vascular territory. Recently, Biasiolli et al. 99 described a method using quantitative T2 mapping to measure the specific physical properties within plaques and enabling their various components to be determined in human carotid atherosclerosis. Combined with DANTE black-blood preparation, 100 which has a superior ability to demonstrate recent IPH, 101 in vivo T2 mapping was shown on a voxel-by-voxel basis, and at high resolution, to enable accurate and highly reproducible non-invasive in vivo quantification of plaque lipid ( Figure 2) . 102 Subsequently, it was shown that despite having similar degree of luminal stenosis, and only a modest difference in terms of plaque volume, 'symptomatic' plaques contain nearly double the amount of lipid compared with Figure 1 Current methods to characterize atherosclerotic plaques, using both invasive and non-invasive techniques. 'asymptomatic' plaques. Encouraging results are now emerging for the potential application of T2 mapping in plaque lipid quantification, which could be useful not just in plaque characterization but, perhaps more importantly, in evaluating response to anti-atherosclerotic treatment. 102 This technique may prove useful as diagnostic/prognostic tool to identify patients with high lipid content within plaque and to guide more rational and individualized treatment. Moreover, it provides the right type of platform for mechanistic staging for new lipid lowering drugs. That said the current proposal of quantifying lipid across vascular tree is still to be tested. Using mechanistic staging should also provide important opportunities for clinical trials-allowing specific hypotheses to be test in smaller numbers of patients (and potentially more rapidly). Data from oncology field have already shown that mechanistic staging is a promising tool. 103 The use of biologic in atherosclerosis is potentially growing and there is larger need to rationalize and tailor these expensive drugs to the individual disease process. Moreover, the use of plaque imaging will facilitate a study where only fewer patients are needed to demonstrate treatment benefits over short period of time. Such effect will have major advantages on patients and health care providers.
Conclusion
Combating the residual risk of thrombo-embolic complications in atherosclerosis remains a significant challenge in the post-statin era; nevertheless, the very idea that atheroma are dynamic entities with progression-and regression-that could be tracked non-invasively in time, has become a reality that could be exploited in 'mechanistic staging'-a concept widely applied in other disciplines in medicine such as in oncology and neurology. At this juncture, novel imaging techniques and stratification technologies are emerging that may soon allow not only the delivery of personalized lipid intervention and antiatherosclerotic treatment, but at a resolution never imagined before. 
